Clinical evaluation of children with celiac disease: A single-center experience

Background and objectives: The clinical fi ndings of Celiac Disease (CD) change over time. Instead of classical symptoms such as diarrhea, growth retardation, abdominal bloating, atypical symptoms such as chronic constipation and abdominal pain may be the only sign of CD. In this study, we aimed to evaluate the clinical features of our patients with CD. Material and methods: This retrospective study was conducted between March 2017 and January 2019. 61 children with CD were included in the study. Local Ethics Committee approval was received. As an initial diagnostic test, tissue transglutaminase antibody (tTG) IgA test and total IgA test were analysed in all patients. Endomysial antibody (EMA) IgA test was analysed in patients with positive tTG IgA. If both celiac tests are detected as positive, gastroduodenoscopy was performed for defi nitive diagnosis of CD. Results: Of the 61 patients, 37 (60.6%) was female. The mean age of patients was 8.28±4.28 years. Tissue transglutaminase antibody (tTG) IgA test was positive in all patients, then endomysial antibody (EMA) IgA test was analysed in those patients. Endomysial antibody IgA test was also positive in all patients except three. The pathological results of our patients were Marsh 3a in 30 patients, Marsh 3b in 19 patients, and Marsh 3c in 12 patients. The positive family history of CD was found in the fi rst degree relatives of 6 asymptomatic patients. Those patients were diagnosed with CD after celiac screening tests and endoscopic biopsy. Most of our patients had more than one symptom; 33 patients (54.1%) had classical symptoms such as failure to thrive and diarrhea, and 25 patients (40.9%) had non-classical symptoms. Conclusion: The fi rst degree relatives of celiac patients even if asymptomatic, and all patients with uncertain complaints and abnormal laboratory fi ndings associated with CD should be evaluated for CD. Research Article Clinical evaluation of children with celiac disease: A singlecenter experience Yasin Sahin* Associate Professor, Pediatric Gastroenterology Clinic, Mersin City Training and Research Hospital, Mersin, Turkey Received: 28 April, 2020 Accepted: 06 May, 2020 Published: 12 May, 2020 *Corresponding author: Yasin Sahin, Associate Professor, Pediatric Gastroenterology Clinic, Mersin City Training and Research Hospital, Mersin, Turkey, Tel: 0532 602 10 63; E-mail: ORCID: https://orcid.org/0000-0002-7394-4884


Introduction
Celiac Disease (CD) is an immune-mediated systemic disease triggered by gluten intake in genetically susceptible individuals and characterised by the combination of various degree of the intestinal damage and the presence of celiac antibodies [1]. Its prevalence is reported to be approximately 1% [1]. The frequency of CD varies according to the geographic region and genetic factors [1]. In a study conducted in healthy school children in our country, the prevalence of CD was reported to be 0.47% [2].
The clinical fi ndings of CD change over time. Instead of classical symptoms such as diarrhea, growth retardation, abdominal swelling, atypical symptoms such as chronic constipation and abdominal pain may be the only sign of celiac disease [1].
The risk of developing CD is higher in type 1 Diabetes Mellitus (DM), Down syndrome, Turner syndrome, autoimmune disorders, and relatives of celiac patients sharing the same type of HLA [3][4][5][6].
The prevalence of CD has increased dramatically over the past 20-30 years due to the use of sensitive and specifi c celiac serological tests and better recognition of CD by physicians. Even if celiac screening tests are recommended in risk groups, the majority of asymptomatic patients are still undiagnosed [7][8][9][10]. In this study, we aimed to evaluate the clinical features of our patients with CD. The fi les, complaints, demographic features, clinical, and laboratory features of patients were examined retrospectively.

Material and methods
As an initial diagnostic test, tissue transglutaminase antibody (tTG) IgA and total IgA tests were analysed in all patients [1]. It is planned to perform tTG IgG in patients with IgA defi ciency [11]. Endomysial Antibody (EMA) IgA test was performed on patients with positive tTG IgA [1]. When used in combination with EMA and tTG IgA tests, the sensitivity and specifi city is close to 95% or more [12].
Gastroduodenoscopy was performed on patients with both positive celiac antibodies to diagnose CD, and at least 4 biopsies from duodenum and 2 biopsies from the bulb were obtained.
The endoscopic biopsies were evaluated according to the Marsh Classifi cation [13].

Statistical analysis
Descriptive statistics were used for frequency, percentage and mean ± standard deviation which are descriptive parameters. Independent-Samples t test was used to compare numerical variables. Mann Whitney U test was used for parameters with non-normal distribution. Statistical Package for Social Sciences for Windows, version 13.0 software (SPSS Inc, Chicago IL, USA) was used for statistical analysis.

Results
Of the 61 patients, 37 (60.6%) was female. The mean age of the patients was 8.28±4.28 years (Table 1) The control endoscopic biopsy was performed 3 months after the eradication therapy of HP, the changes of Marsh 3a were detected in the duodenum, and then CD was diagnosed.
The positive family history of CD was found in the fi rst degree relatives of 6 asymptomatic patients. Those patients without any symptoms were diagnosed with CD after celiac screening tests and gastroduodenoscopy.
One of our patients, who has positive family history of CD, presented with growth retardation. Both tTG and EMA antibodies IgA tests were found as positive. Gastroduodenoscopy was performed on this patient, multiple millimetric ulcers were detected in the corpus, and Marsh 0 classifi cation score was detected in the duodenum and bulbus. After six months,   The endoscopic biopsy revealed Marsh 3a compatible with CD, and then she was diagnosed with CD.
presented with extraintestinal or atypical fi ndings such as anemia, osteoporosis, dermatitis herpetiformis, neurological problems, and dental enamel hypoplasia [15]. Marsh 3a compatible with CD. Then, the patient who applied with atypical symptoms, was also diagnosed with CD in accordance with literature [16,17].
Approximately 10% of the positive family history of CD was reported in the fi rst degree relatives of celiac patients [18,19].
In parallel with these studies, 6 of our patients (9.83%) had a positive family history of CD in their fi rst degree relatives.
Of the patients, 39.7% had growth retardation, 18.9% had anemia, and 12.1% had constipation in a recent study [20].
In consistent with this study, 28 of our patients (45.9%) had growth retardation, 9 of our patient (14.7%) had anemia and 9 of our patients (14.7%) had constipation.
Most of our patients had more than one symptom in consistent with literature (1,18,19); the classical symptoms such as failure to thrive and diarrhea in 33 patients (54.1%), and non-classical symptoms in 25 patients (40.9%) was detected.
It has been reported to be 10.8-62.0% of newly diagnosed celiac patients have vitamin D defi ciency (18,21,22). In the current study, vitamin D defi ciency was found in 38 of our patients (62.2%). The reason for high rate of vitamin D defi ciency detected in our patients may be due to insuffi cient use of sunlight, the high number of our patients with low socio-economic level, and related to malnutrition.

Discussion
In a systematic review and meta-analysis, the prevalence of biopsy-proven CD was reported to be 0.7% and its seroprevalence 1.4% [14].
Celiac patients can also present with gastrointestinal symptoms, extraintestinal symptoms or without any symptoms. The classical fi ndings of CD related to the gastrointestinal system are weight loss, steatorrhea and diarrhea due to malabsorption [1]. Approximately 50% of celiac patients Iron defi ciency anemia is a typical complication of malabsorption in CD [23]. As compatible with literature, 8 of our patients (13.1%) had refractory iron defi ciency anemia at the time of diagnosis.
The intensity of the pathological lesion is from proximal to distal in CD. Sometimes, villous atrophy is seen only in the bulbus mucosa [24][25][26]. In accordance with the literature, the pathological fi ndings compatible with CD were detected only in the bulbus mucosa of 8 patients (13.1%) in the current study. Therefore, at least 4 biopsies from the duodenum and 2 biopsies from the bulb should be obtained from patients who are considered to have CD, while considering that pathological fi ndings of CD may be seen only in the bulb.
As celiac patients can present with gastrointestinal system symptoms, extraintestinal symptoms, atypical fi ndings or without symptoms, the majority of celiac patients are still not diagnosed [14,[27][28][29].
In our study, 20 patients (32.7%) in the CD risk group were either asymptomatic or presented with atypical fi ndings, and then diagnosed with CD as a result of careful assessment. As compatible with literature, approximately 1/4 of our patients presented with atypical symptoms such as chronic abdominal pain and constipation, and those symptoms were mostly present in older children [1,16,17].

Conclusion
The majority of celiac patients are still undiagnosed, patients diagnosed with CD constitute only the tip of the iceberg. Those patients have the risk of developing long-term complications of CD such as growth retardation, infertility, osteoporosis, and malignancies. To prevent these long-term complications, early diagnosis of CD is crucial. In the current study, approximately 1/3 of our patients diagnosed with CD were either asymptomatic or presented with atypical fi ndings.
All patients with atypical symptoms or vague symptoms, with abnormal laboratory fi ndings associated with CD, and those who are in the risk group for CD even if asymptomatic, should be carefully evaluated for CD.